Industry Outlook and Trend Analysis

The HIV Vaccines Market was worth USD 1.23 billion in 2014 and is expected to reach approximately USD 1.95 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 5.30% during the forecast period. Antibodies are among the most ground-breaking and savvy illness anticipation instruments. An antibody that could keep the HIV contamination or stop the advancement of the infection would significantly bolster in the battle against the AIDS ailment. Immunizations have been pivotal in overall smallpox disposal endeavours, have almost dispensed with polio and have definitely decreased the frequency of irresistible infections like measles and pertussis in the US. In any case, the inquiry is emerging that whether HIV antibody ought to be created for a solitary strain or it ought to be intended for differed strain structures. The entire point is to give the better drug to the annihilation of the infection using necessary means.

Drivers & Restrains

The worldwide market for HIV antibody is one of the quickest developing markets. In spite of the fact that there is no business HIV immunization accessible in the market; there is tremendous financing for the exploration and advancement of HIV antibody. The development of the market is probably going to drive by rising Research and development subsidizing for HIV antibody, rising predominance of HIV because of prostitution, expanding awareness because of HIV counteractive action programs, developing number of new contestants in the market.

Regional Outlook and Trend Analysis

North America is expected to witness considerable growth over the forecast period. The substantial size of the market can be credited to higher selection of different HIV immunization preliminaries combined with nearness of technological advancement. Europe is the second-biggest market for HIV antibody which is expected to take up good growth. Asia-Pacific HIV market is required to develop with a relentless pace.

Competitive Insights

The leading players in the market are Janssen Global Services, Llc , Argos Therapeutics, Inc., Paxvax Corporation, Geovax, Glaxosmithkline Plc and others. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

The HIV Vaccines Market is segmented as follows-

By Clinical Trials:


Phase I
Phase II
Phase III


By Region


North America


U.S.
Canada
Mexico


Europe

Germany
UK
France
Russia
Italy
Rest of Europe


Asia-Pacific

China
Japan
South Korea
India
Southeast Asia
Rest of Asia-Pacific


South America

Brazil
Argentina
Columbia
South Africa
Rest of South America


Middle East and Africa

Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Rest of MEA




Some of the key questions answered by the report are:


What was the market size in 2014 and forecast from 2015 to 2023?
What will be the industry market growth from 2015 to 2023?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?